Senior Scientist, Bio AI

Earli tackles the #1 problem in the $100B cancer drug market: systemic toxicity. On-target/off-tumor effects force suboptimal dosing, reduced efficacy and sidelining some of the most potent drug classes such as cytokines. Earli’s BioAI approach flips this paradigm: Drugs are produced only where needed—in the tumor, by the tumor, against the tumor. Cancer cells become their own drug factories, enabling localized immune activation, even in cold tumors.

• You share our same sense of dedication, scientific passion and entrepreneurial spirit
• You work well in a fast-paced and extremely focused startup environment
• You are not only smart, but clever and constantly think outside the box
• You are able to make logical decisions in an instant when there is little time to evaluate
• You are a natural communicator and relationship builder
• You stay calm under high pressure and stress
• You have the ability to multi-task in a serious way, with an extreme attention to detail